| Literature DB >> 31291896 |
Yu-Xin Liu1, Qiu-Mei Cao2, Bing-Chen Ma3.
Abstract
BACKGROUND: This study aims to investigate the pathogen distribution and drug resistance in patients with acute cerebral infarction complicated with diabetes mellitus and nosocomial pulmonary infection.Entities:
Keywords: Acute cerebral infarction; Diabetes mellitus(DM); Drug-resistance; Pathogen; Pulmonary infection
Mesh:
Substances:
Year: 2019 PMID: 31291896 PMCID: PMC6617900 DOI: 10.1186/s12879-019-4142-9
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
The distribution of pathogens in all nosocomial infections in the hospital
| Key pathogenic bacteria | Year | ||
|---|---|---|---|
| 2015 (%) | 2016 (%) | 2017 (%) | |
|
| 10.14 | 18.01 | 17.50 |
|
| 15.65 | 16.91 | 13.88 |
|
| 9.57 | 10.29 | 12.15 |
| Baumanii | 8.99 | 7.35 | 7.38 |
|
| 4.93 | No | 5.42 |
|
| 3.48 | 6.99 | 5.21 |
|
| 26.38 | No | 77.0 |
|
| 4.64 | 5.51 | 4.34 |
The characteristics of cerebral infarction patients in the diabetic and non-diabetic groups
| Groups | Diabetic group ( | Non-diabetic group ( | P |
|---|---|---|---|
| Age | 75.35 ± 6.224 | 74.91 ± 10.799 | 0.752 |
| Gender(Male/Female) | 32/28 | 50/42 | 0.959 |
| NIHSS score | 17.03 ± 1.149 | 16.8 ± 1.260 | 0.259 |
The distribution and proportion of pathogenic bacteria
| Pathogenic bacteria | Diabetic group | Non-diabetic group |
|---|---|---|
| Number of case(Constituent ratio %) | Number of case(Constituent ratio %) | |
| Gram-negative bacterium | 60 (80.0) | 70 (72.2) |
| Baumanii | 27 (36.0) | 32 (33) |
| Klebsiella Pneumoniae | 7 (9.3) | 5 (5.2) |
| Pseudomonas Aeruginosa | 13 (17.3) | 19 (19.5) |
| Escherichia coli | 7 (9.3) | 6 (6.2) |
|
| 2 (2.7) | 1 (1) |
| Acinetobacter Pistorii | 1 (1.3) | 4 (4.1) |
| Others | 3 (4.0) | 3 (3.1) |
| Gram-positive Bacterium | 11 (14.7) | 22 (22.6) |
| Staphylococcus aureus | 5 (6.7) | 15 (15.5) |
|
| 4 (5.3) | 4 (4.1) |
| Enterococcus Faecium | 2 (2.7) | 3 (3.1) |
| Fungus | 4 (5.3) | 5 (5.2) |
| Candida albicans | 2 (2.6) | 3 (3.1) |
| Candida lucidum | 1 (1.3) | 2 (2.1) |
| Total | 75 | 97 |
| Statistic | x2 = 21.253 | P = 0.001 |
Resistance rate of major gram-negative bacilli to commonly used drugs(%)
| Name of drug | Diabetic group | Non-diabetic group |
|---|---|---|
| Imipenem | 38.4 | 25.9 |
| Piperacillin and Sulbactam | 68.2 | 55.9 |
| Piperacillin and Tazobactam | 49.7 | 59.6 |
| ceftazidime | 82.5 | 54.6 |
| ceftriaxone | 91.7 | 78.9 |
| Ciprofloxacin | 95.6 | 66.1 |
| amikacin | 50.8 | 42.7 |
| Trimethoprim/sulfonamide | 85.6 | 64.1 |
| gentamicin | 83.3 | 70.3 |
| levofloxacin | 61.6 | 50.8 |
| tobramycin | 44 | 28.6 |
| drug-resistance rates | 68.3 | 54.3 |
Resistance rate of major gram-positive cocci to antibiotics(%)
| Name of drug | Diabetic group | Non-diabetic group |
|---|---|---|
| levofloxacin | 0 | 0 |
| levofloxacin | 70.5 | 38.2 |
| linezolid | 0 | 0 |
| vancomycin | 0 | 0 |
| penicillin | 100 | 80 |
| tetracycline | 51.6 | 36.3 |
| Piperacillin and Sulbactam | 60.9 | 50.6 |
| erythrocin | 58.3 | 15.4 |
| oxacillin | 83.8 | 62.6 |
| rifampicin | 35.4 | 12.9 |
| cefazolin | 82.7 | 60.3 |
| moxifloxacin | 25.2 | 5.6 |
| Trimethoprim/sulfonamide | 23.3 | 4.8 |
| drug-resistance rates | 45.5 | 28.2 |
Comparison of drug resistance rates between the two groups
| Diabetic group | Non-diabetic group | |
|---|---|---|
| Drug resistance rate of gram-negative bacilli | 68.3% | 54.3% |
| Drug resistance rate of gram-positive cocci | 45.5% | 28.2% |
| Statistic | x2 = 8.817 | P = 0.003 |